EUVIMED · CrossrefZeitschrift
ESMO Rare Cancers
ISSN 3050-4619 · Elsevier BV
Neueste Artikel
Long-term impact of sporadic desmoid fibromatosis on work life, reproductive health, and support needs: results from the PROSa-DES study
The rare cancer ‘zebra’ advantage: flipping the script for success in oncology drug development
Unusual metastatic patterns in gastrointestinal stromal tumors: a multicenter analysis from the Dutch GIST Registry
Enteric-type urachal adenocarcinoma harboring an EIF3E::RSPO2 fusion with durable response to immune checkpoint inhibition: a case report
Prolonged disease control with trabectedin in metastatic EWSR1::PATZ1 sarcoma: a case report
Durable response to bicalutamide, goserelin, and dutasteride for androgen receptor-positive metastatic salivary duct carcinoma: a case report
Enhancing the attractiveness of sarcoma drug development: from rare disease to high-value development platform
Epidemiology of sinonasal undifferentiated carcinoma in Queensland, Australia, 1982-2024: insights from a population-based cohort
A case of mucinous adenocarcinoma of the prostate: pathological complete response achieved with intensity-modulated radiation therapy
Feasibility of active surveillance for atypical lipomatous tumors and impact on quality of life: interim analysis of the MINIMALIST trial
Novel therapeutics and surrogate endpoints in chondrosarcoma: a retrospective analysis of patients enrolled in phase I/II trials
Using liver-directed therapies as backbone for combination-treatments in metastatic uveal melanoma
Palliative systemic chemotherapy in peritoneal mesothelioma: a retrospective efficacy analysis of the RENAPE database
Adding testosterone to tamoxifen in metastatic male breast cancer: the prospective, single-arm T&T pilot trial
Long-term response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer: a case report
Precision oncology in salivary gland cancer: molecular landscape, therapeutic advances and emerging strategies
288MO Update from the long-term follow-up (LTFU) phase of ReNeu: A pivotal phase IIb trial of mirdametinib in adults and children with neurofibromatosis type 1 (NF1)-associated symptomatic plexiform neurofibroma (PN)
Thymic epithelial tumors: what’s new and what’s next?
Stage shift from Masaoka-Koga to ninth TNM system in thymic epithelial tumors
ESMO Rare Cancers – a brighter future for patients with rare cancers
Advances in alveolar soft part sarcoma treatment in the era of immunotherapy
The urgent need to redefine quality of life in patients with low-grade glioma
Neuropsychiatric manifestations of adrenocortical carcinoma: a review and case report of adrenocortical carcinoma causing mania
Table of Contents
Editorial Board
EP300::VGLL3 rhabdomyosarcoma: a potential distinct indolent adult rhabdomyosarcoma subtype
Hypokalaemia and hypercortisolaemia at diagnosis are negative prognostic factors: a retrospective analysis of the medical management of ectopic Cushing syndrome
The European Prospective Investigation into Cancer and Nutrition Cohort (EPIC): a gateway to rare cancer epidemiological research
Mirdametinib approval for neurofibromatosis type 1 with inoperable plexiform neurofibromas: the journey of MEK inhibitors
Emerging therapies for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas
EUVIMED